Exelixis Highlights $2.4B 2026 Outlook, Cabometyx Momentum and Zanzalintinib Catalysts at Conference [Yahoo! Finance]
Exelixis, Inc. (EXEL)
Last exelixis, inc. earnings: 2/25 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.exelixis.com/phoenix.zhtml?c=120923&p=irol-mediaresources
Company Research
Source: Yahoo! Finance
billion , forecasting growth driven by its Cabometyx renal cell carcinoma (RCC) franchise and the recent neuroendocrine tumor (NET) launch, which the company sees as an approximately $1 billion oral-segment opportunity. Management highlighted zanzalintinib as a potential $5 billion opportunity with a broadened program now comprising seven pivotal studies , spanning GU and GI cancers, and flagged STELLAR-303 (late-line CRC) ahead of a potential December PDUFA as a commercially important, chemo-free checkpoint-containing regimen. On RCC competition, Exelixis characterized Merck's LITESPARK-011 update as “not practice-changing,” arguing overall survival will determine whether combinations supplant sequencing, and noting combination regimens add toxicity and saw meaningful discontinuation (about discontinued one agent). Interested in Exelixis, Inc.? Here are five stocks we like better. Exelixis Reports Solid Earnings—Are New Highs Back on the Table? Exelixis (NASDAQ:EXEL) detail
Show less
Read more
Impact Snapshot
Event Time:
EXEL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EXEL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EXEL alerts
High impacting Exelixis, Inc. news events
Weekly update
A roundup of the hottest topics
EXEL
News
- Exelixis (EXEL) Valuation After Earnings Beat FDA Progress And Cabometyx Label Expansion [Yahoo! Finance]Yahoo! Finance
- Exelixis Highlights Zanzalintinib RCC Trials, Sequencing Debate, and December CRC PDUFA at Leerink [Yahoo! Finance]Yahoo! Finance
- Exelixis Highlights CABOMETYX Growth, Zanzalintinib PDUFA and Pipeline Strategy at Barclays Conference [Yahoo! Finance]Yahoo! Finance
- Here's Why Exelixis (EXEL) is a Strong Growth Stock [Yahoo! Finance]Yahoo! Finance
- Exelixis, Inc. (EXEL) Presents at Barclays 28th Annual Global Healthcare Conference Transcript [Seeking Alpha]Seeking Alpha
EXEL
Earnings
- 2/10/26 - Beat
EXEL
Sec Filings
- 3/2/26 - Form 4
- 3/2/26 - Form 4
- 3/2/26 - Form 4
- EXEL's page on the SEC website